

MEDAREX INC  
Form 8-K  
April 28, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 25, 2008**

**MEDAREX, INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**  
(State or other jurisdiction  
of incorporation)

**0-19312**  
(Commission  
File Number)

**22-2822175**  
(IRS Employer  
Identification No.)

**707 State Road, Princeton, N.J.**  
(Address of principal executive offices)

**08540-1437**  
(Zip Code)

Registrant's telephone number, including area code: **(609) 430-2880**

**N/A**  
(Former name or former address, if changed since last report.)

## Edgar Filing: MEDAREX INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On April 25, 2008, Medarex, Inc. and Bristol-Myers Squibb Company issued a press release to announce a delay in the Biologics License Application submission for ipilimumab, an investigational immunotherapy for patients with advanced metastatic melanoma.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following press release is furnished as an exhibit to this Current Report:

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press release issued April 25, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDAREX, INC.**

Date: April 25, 2008

/s/ Christian S. Schade  
Christian S. Schade,  
Senior Vice President and Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit**

**Number**

**Description**

99.1 Press release issued April 25, 2008.

4

---